Search Site

Trends banner

TSMC first-quarter net profit soars

Its net revenue for the quarter soared nearly 42%.

Tesla’s first Saudi showroom opens

The opening in Riyadh comes with Tesla sales dropping.

Mubadala Energy enters US energy market

Acquires a 24.1% interest in US firm Kimmeridge’s SoTex

Borouge to increase dividend from 2025

The company okayed $650 million final dividend for 2024.

TikTok’s US future uncertain

It must find non-Chinese owner to avoid ban.

UAE children aged 3-17 to receive Chinese Sinopharm vaccine

    • The Gulf state, which has among the world’s highest immunization rates, was already providing the Pfizer-BioNTech vaccine for children aged 12-15

    • The UAE government took to twitter to make the announcement

    The United Arab Emirates has decided to inoculate children between the ages of 3 and 17 with Chinese Covid-19 vaccine Sinopharm. Although the Chinese vaccines have been criticized for their low efficacy, the UAE was still going ahead to vaccinate the younger children with the Sinopharm vaccine.

    The UAE government took to twitter to make the announcement. It cited the health ministry as saying the decision comes after clinical trials and extensive evaluations, without providing any details. Authorities said in June the trial would monitor the immune response of 900 children.

    The Gulf state, which has among the world’s highest immunization rates, was already providing the Pfizer-BioNTech vaccine for children aged 12-15.

    The health ministry said on Sunday that 78.95 percent of the UAE population of roughly 9 million had received one vaccine dose while 70.57 percent had been fully vaccinated.

    The UAE, the region’s tourism and trade hub, registered 1,519 new coronavirus infections on Sunday to take its total to 682,377 cases and 1,951 deaths. It does not provide a breakdown for each of its seven emirates.

    It led Phase III clinical trials of the vaccine produced by China’s state-owned drugmaker Sinopharm and has started manufacturing it under a joint venture between Sinopharm and Abu Dhabi-based technology company Group 42.